Status:
NOT_YET_RECRUITING
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans
Lead Sponsor:
Mayo Clinic
Conditions:
Genetic Predisposition
Type2diabetes
Eligibility:
All Genders
25-70 years
Phase:
PHASE2
Brief Summary
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are...
Detailed Description
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. This supports oth...
Eligibility Criteria
Inclusion
- Subjects with the TT or CC genotype at rs7903146
Exclusion
- Age \< 25 or \> 70 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
- CT genotype at rs7903146
- HbA1c \> 6.5%
- Use of any glucose-lowering agents including metformin or sulfonylureas.
- For female subjects: positive pregnancy test at the time of enrollment or study.
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2029
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06972407
Start Date
December 1 2025
End Date
March 1 2029
Last Update
October 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905